Smoothelin is a specific marker for smooth muscle neoplasms of the gastrointestinal tract

American Journal of Surgical Pathology

Volumn 33, Issue 12, 2009, Pages 1795-1801

  Coco, Dominique P ^a   Hirsch, Michelle S ^a   Hornick, Jason L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gastrointestinal stromal tumor; Gastrointestinal tract; Leiomyoma; Leiomyosarcoma; Muscularis; Smooth muscle; Smoothelin

Indexed keywords

CYTOSKELETON PROTEIN; DESMIN; MUSCLE PROTEIN; SMTN PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CELL NUCLEUS; CHEMISTRY; CYTOPLASM; DIFFERENTIAL DIAGNOSIS; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MUSCLE TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY;

CELL DIFFERENTIATION; CELL NUCLEUS; CYTOPLASM; CYTOSKELETAL PROTEINS; DESMIN; DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MUSCLE PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-KIT; SENSITIVITY AND SPECIFICITY; SMOOTH MUSCLE TUMOR; TUMOR MARKERS, BIOLOGICAL;

EID: 73349092437     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181b76477     Document Type: Article

References (18)

1. Amiot A, Cazals-Hatem D, Joly F, et al. The role of immuno-histochemistry in idiopathic chronic intestinal pseudoobstruc-tion (CIPO): a case-control study. Am J Surg Pathol. 2009;33: 749-758.
2. Council L, Hameed O. Differential expression of immuno-histochemical markers in bladder smooth muscle and myofibro-blasts, and the potential utility of desmin, smoothelin, and vimentin in staging of bladder carcinoma. Mod Pathol. 2009;22: 639-650.
3. Demetri GD, von MM, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
4. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338.
5. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32:210-218.
6. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
7. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580. (Pubitemid 28067289)
8. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660-667.
9. Kramer J, guirre-Arteta AM, Thiel C, et al. A novel isoform of the smooth muscle cell differentiation marker smoothelin. J Mol Med. 1999;77:294-298.
10. Kramer J, Quensel C, Meding J, et al. Identification and characterization of novel smoothelin isoforms in vascular smooth muscle. J Vasc Res. 2001;38:120-132.
11. Liegl B, Hornick JL, Corless CL, et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 2009;33:437-446.
12. Maake C, Landman M, Wang X, et al. Expression of smoothelin in the normal and the overactive human bladder. J Urol. 2006;175: 1152-1157.
13. Niessen P, Rensen S, van DJ, et al. Smoothelin-a is essential for functional intestinal smooth muscle contractility in mice. Gastro-enterology. 2005;129:1592-1601.
14. Paner GP, Shen SS, Lapetino S, et al. Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol. 2009;33:91-98.
15. Rensen SS, Thijssen VL, De Vries CJ, et al. Expression of the smoothelin gene is mediated by alternative promoters. Cardiovasc Res. 2002;55:850-863.
16. van der Loop FT, Schaart G, Timmer ED, et al. Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J Cell Biol. 1996;134:401-411.
17. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet. 2004;364:1127-1134.
18. Wedel T, van Eys GJ, Waltregny D, et al. Novel smooth muscle markers reveal abnormalities of the intestinal musculature in severe colorectal motility disorders. Neurogastroenterol Motil. 2006;18: 526-538.